AOD-9604 Synthesis Verification: Testing C-Terminal Lipolytic Fragment Sequences

 

AOD-9604 is a synthetic hexadecapeptide derived from the C-terminal region of human growth hormone (hGH), specifically corresponding to residues 176–191. Unlike full-length hGH, which binds the growth hormone receptor and stimulates systemic IGF-1 production, AOD-9604 was designed to isolate the lipolytic domain of hGH while avoiding its growth-promoting and diabetogenic effects. For researchers sourcing this peptide, verifying both the synthetic fidelity of the sequence and the functional integrity of the lipolytic fragment is essential for generating reproducible data.

The C-Terminal Fragment: Sequence and Structural Features

The native C-terminal lipolytic domain of hGH spans residues 177–191, terminating with the sequence Gly-Phe-OH. AOD-9604 incorporates two key modifications relative to this native fragment. First, a tyrosine residue is added at the N-terminus, replacing the native phenylalanine at position 176, which provides a spectrophotometric handle for analytical detection (tyrosine absorbs at 280 nm) while maintaining biological activity. Second, the peptide contains a critical intramolecular disulphide bond between Cys7 and Cys14, creating a cyclic loop that constrains the three-dimensional conformation and is essential for lipolytic activity.

The complete sequence is H-Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-OH, with the disulphide bridge connecting Cys7 and Cys14. This 16-amino-acid structure has a molecular formula of C₇₈H₁₂₃N₂₃O₂₃S₂ and a monoisotopic mass of approximately 1815.1 Da for the free base.

Synthesis Verification: From Resin to Final Product

AOD-9604 is manufactured using standard Fmoc solid-phase peptide synthesis (SPPS), typically starting from a Wang-Phe-Fmoc resin or 2-Cl-Trt resin preloaded with the C-terminal phenylalanine. The synthesis proceeds through sequential coupling of Fmoc-protected amino acids, with trifunctional residues protected as follows: Tyr(tBu), Arg(Pbf), Ser(tBu), Cys(Trt), and Cys(Acm).

A critical challenge in AOD-9604 synthesis is the regioselective formation of the disulphide bond. The synthesis typically employs orthogonal cysteine protection: one cysteine protected with acid-labile Trt and the other with Acm. After chain assembly and cleavage from the resin, the Acm group is removed and the disulphide bond is formed via iodine oxidation in acetic acid, followed by preparative RP-HPLC purification to >98.5% purity.

The FDA has noted that AOD-9604 is "not physically and chemically well characterised" due to the absence of critical characterisation data in public literature and Certificates of Analysis, including specific tests for peptide-related impurities, aggregates, microbial limits, and bacterial endotoxin. The disulphide bridge itself poses a degradation risk—reduction of the disulphide bond can lead to aggregate formation, and peptide-related impurities may be difficult to identify without sophisticated analytical methods.

Analytical Verification Methods

Mass spectrometry provides the primary identity confirmation. The theoretical mass for AOD-9604 free base is 1815.0 Da, with the [M+H]⁺ ion expected at m/z 1815. 2. ESI-MS analysis of a compliant batch should show this value within acceptable tolerance. For the acetate salt form, the molecular weight increases to approximately 1875.1 Da due to the acetate counterion.

Peptide mapping with LC-MS/MS offers the most rigorous sequence verification. Following enzymatic digestion (typically with trypsin), the resulting fragments are analysed by tandem mass spectrometry, and the b- and y-ion series reconstruct the complete amino acid sequence. This approach also confirms the correct placement of the disulphide bond, which is critical because incorrect disulphide connectivity would produce a structurally distinct molecule with potentially altered activity.

RP-HPLC purity determination at 214 nm establishes the proportion of full-length peptide relative to truncation and deletion impurities. A representative Certificate of Analysis for a research-grade batch report 99.1% purity by RP-HPLC, with sequence confirmation by MS/MS, endotoxin below 0.25 EU/mg, and microbial limits compliant with USP <61>/<62>.

Functional Assays for the Lipolytic Fragment

The C-terminal fragment of hGH exerts its lipolytic effects through a mechanism distinct from full-length hGH. AOD-9604 does not bind the classical growth hormone receptor with high affinity and does not stimulate hepatic IGF-1 transcription. Instead, research suggests it interacts with beta-3 adrenergic receptors (ADRB3) on adipocytes, activating adenylyl cyclase and increasing intracellular cAMP. This triggers protein kinase A (PKA), which phosphorylates hormone-sensitive lipase (HSL) and perilipin, leading to translocation of HSL to the lipid droplet surface and hydrolysis of triacylglycerols into free fatty acids and glycerol.

In vitro lipolysis assays using adipose tissue explants or cultured adipocytes provide functional verification. AOD-9604 has demonstrated lipolytic activity in adipose tissue from multiple species, including rodent, human, pig, and dog. For researchers establishing functional comparability of a sourced preparation, these assays confirm that the peptide retains its biological activity independent of its structural identity.

Practical Considerations for Researchers

When evaluating AOD-9604 from any supplier, the documentation package should include batch-specific HPLC chromatograms with purity percentage, mass spectrometry data confirming molecular weight, and ideally peptide mapping or MS/MS sequence data with explicit confirmation of the disulphide bond. Given the FDA's observation that AOD-9604 is difficult to characterise and that disulphide reduction can lead to aggregation, researchers should also consider requesting size exclusion chromatography (SEC) or field flow fractionation data to assess aggregate content.

The structural separation of somatotropic growth from lipid catabolism that AOD-9604 embodies makes it a useful tool for studying isolated lipolytic pathways. However, its utility depends on rigorous verification that the C-terminal fragment is intact, correctly cyclised, and free from synthesis-related impurities that could confound experimental results.